Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients.
Vetter M, Rothgiesser KM, Li Q, Hawle H, Schönfeld W, Ribi K, Riniker S, von Moos R, Trojan A, Kralidis E, Fehr M, Müller A, Thürlimann B; Swiss Group for Clinical Cancer Research (SAKK). Vetter M, et al. Among authors: von moos r. Endocr Oncol. 2022 Feb 10;2(1):9-18. doi: 10.1530/EO-21-0009. eCollection 2022 Jan. Endocr Oncol. 2022. PMID: 37435469 Free PMC article.
Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study.
Strasser F, Lutz TA, Maeder MT, Thuerlimann B, Bueche D, Tschöp M, Kaufmann K, Holst B, Brändle M, von Moos R, Demmer R, Cerny T. Strasser F, et al. Among authors: von moos r. Br J Cancer. 2008 Jan 29;98(2):300-8. doi: 10.1038/sj.bjc.6604148. Epub 2008 Jan 8. Br J Cancer. 2008. PMID: 18182992 Free PMC article. Clinical Trial.
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06).
Rochlitz C, Ruhstaller T, Lerch S, Spirig C, Huober J, Suter T, Bühlmann M, Fehr M, Schönenberger A, von Moos R, Winterhalder R, Rauch D, Müller A, Mannhart-Harms M, Herrmann R, Cliffe B, Mayer M, Zaman K; Swiss Group for Clinical Cancer Research (SAKK). Rochlitz C, et al. Among authors: von moos r. Ann Oncol. 2011 Jan;22(1):80-85. doi: 10.1093/annonc/mdq319. Epub 2010 Jul 1. Ann Oncol. 2011. PMID: 20595448 Free article. Clinical Trial.
Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03).
Koeberle D, Ruhstaller T, Jost L, Pagani O, Zaman K, von Moos R, Oehlschlegel C, Crowe S, Pilop C, Thuerlimann B; Swiss Group for Clinical Cancer Research (SAKK). Koeberle D, et al. Among authors: von moos r. Endocr Relat Cancer. 2011 Mar 9;18(2):257-64. doi: 10.1530/ERC-10-0317. Print 2011 Apr. Endocr Relat Cancer. 2011. PMID: 21317203 Clinical Trial.
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
von Moos R, Seifert B, Simcock M, Goldinger SM, Gillessen S, Ochsenbein A, Michielin O, Cathomas R, Schläppi M, Moch H, Schraml PH, Mjhic-Probst D, Mamot C, Schönewolf N, Dummer R; Swiss Group for Clinical Cancer Research (SAKK). von Moos R, et al. Ann Oncol. 2012 Feb;23(2):531-6. doi: 10.1093/annonc/mdr126. Epub 2011 Apr 28. Ann Oncol. 2012. PMID: 21527587 Free article. Clinical Trial.
Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma.
Dummer R, Guggenheim M, Arnold AW, Braun R, von Moos R; Project Group Melanoma of the Swiss Group for Clinical Cancer Research. Dummer R, et al. Among authors: von moos r. Swiss Med Wkly. 2011 Dec 15;141:w13320. doi: 10.4414/smw.2011.13320. eCollection 2011. Swiss Med Wkly. 2011. PMID: 22180245 Free article.
165 results